Latest In

News

How Artificial Intelligence Unlocks New Advancements In Anti-Aging Medicine

A recent publication in Nature Aging, authored by researchers from Integrated Biosciences, sheds light on how artificial intelligence unlocks new advancements in anti-aging medicine, promising intersection of synthetic biology, machine learning, and aging research.

Landon Morton
Jul 17, 20232089 Shares59677 Views
A recent publication in Nature Aging, authored by researchers from Integrated Biosciences, sheds light on how artificial intelligence unlocks new advancements in anti-aging medicinepromising intersection of synthetic biology, machine learning, and aging research.
The study showcases the application of artificial intelligence (AI) in the discovery of novel senolytic compounds. Senolytics, a class of small molecules garnering considerable attention, hold the potential to impede various aging-related processes such as fibrosis, inflammation, and cancer.
This groundbreaking research emerged from a collaborative endeavor involving scientists from the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard. The paper describes the implementation of AI-driven analysis on an extensive library of more than 800,000 compounds. As a result, the study successfully identified three potential drugs exhibiting comparable efficacy to existing senolytics under investigation, while also demonstrating superior medicinal chemistry properties.
This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery. These data demonstrate that we can explore chemical space in silicoand emerge with multiple candidate anti-aging compounds that are more likely to succeed in the clinic, compared to even the most promising examples of their kind being studied today.- Felix Wong, Ph.D., co-founder of Integrated Biosciences and first author of the publication
Senolytics are a class of substances that have the ability to trigger programmed cell death, known as apoptosis, specifically in senescent cells that are no longer dividing. Senescent cells, which are a characteristic of aging, have been associated with various age-related diseases and conditions such as cancer, diabetes, cardiovascular disease, and Alzheimer's disease.
A robot wearing a doctor's attire while holding a note with a stethoscope round its neck
A robot wearing a doctor's attire while holding a note with a stethoscope round its neck
Despite showing promising results in clinical trials, the development of senolytic compounds has faced challenges due to limited bioavailability and undesirable side effects. In order to address these obstacles and target other neglected aspects of aging, Integrated Biosciences was established in 2022.
This innovative company aims to leverage artificial intelligence, synthetic biology, and other cutting-edge tools to advance the development of anti-aging drugs and overcome the limitations faced by existing senolytic compounds.
One of the most promising routes to treat age-related diseases is to identify therapeutic interventions that selectively remove these cells from the body similarly to how antibiotics kill bacteria without harming host cells. The compounds we discovered display high selectivity, as well as the favorable medicinal chemistry properties needed to yield a successful drug. We believe that the compounds discovered using our platform will have improved prospects in clinical trials and will eventually help restore health to aging individuals.- Satotaka Omori, Ph.D., Head of Aging Biology at Integrated Biosciences and joint first author of the publication
In a recent study conducted by researchers at Integrated Biosciences, deep neural networks were utilized to train on experimentally generated data, enabling the prediction of senolytic activity for any given molecule. Leveraging this AI model, the researchers successfully identified three highly potent and selective senolytic compounds from a vast chemical space comprising more than 800,000 molecules.
These three compounds demonstrated favorable chemical properties, suggesting they have a high likelihood of being absorbed orally, and they exhibited promising toxicity profiles based on hemolysis and genotoxicity tests. Through structural and biochemical analyses, it was determined that all three compounds interact with Bcl-2, a protein responsible for regulating apoptosis and commonly targeted in chemotherapy.
In further experiments conducted on 80-week-old mice, which roughly correspond to 80-year-old humans, one of the compounds was found to effectively clear senescent cells and decrease the expression of genes associated with senescence in the kidneys. This groundbreaking research showcases the potential of AI-driven drug discovery in identifying promising senolytic compounds with enhanced properties, paving the way for advancements in the field of anti-aging therapeutics.

Conclusion

"This work illustrates how AI can be used to bring medicine a step closer to therapies that address aging, one of the fundamental challenges in biology," said James J. Collins, Ph.D., Termeer Professor of Medical Engineering and Science at MIT and founding chair of the Integrated Biosciences Scientific Advisory Board.
"Integrated Biosciences is building on the basic research that my academic lab has done for the last decade or so, showing that we can target cellular stress responses using systems and synthetic biology. This experimental tour de force and the stellar platform that produced it make this work stand out in the field of drug discovery and will drive substantial progress in longevity research."
Jump to
Latest Articles
Popular Articles